CUDA Yanqi Lake Conference | Exclusive Interview with Professor Hong Liao: In the Era of Precision Therapy for Prostate Cancer, How Do We Move from “Experience-Driven” to “Evidence-Driven” Care?

CUDA Yanqi Lake Conference | Exclusive Interview with Professor Hong Liao: In the Era of Precision Therapy for Prostate Cancer, How Do We Move from “Experience-Driven” to “Evidence-Driven” Care?

Prostate cancer is the second most commonly diagnosed malignancy and the fifth leading cause of cancer-related death among men worldwide. In recent years, with the rapid advancement of molecular biology technologies and the emergence of novel therapeutic agents, prostate cancer management has officially entered the era of precision medicine. Clinical decision-making is undergoing a profound transformation—from the traditional “one-size-fits-all” approach to individualized treatment strategies guided by precise staging and molecular profiling.
CUDA Yanqi Lake Conference | From Personal Mastery to Broader Impact: The Growth and Legacy of a Urologic Surgeon

CUDA Yanqi Lake Conference | From Personal Mastery to Broader Impact: The Growth and Legacy of a Urologic Surgeon

The 2026 Yanqi Lake Academic Conference for Urologists was successfully held in Beijing. During the meeting, Conference Chair Professor Nianzeng Xing, Vice President of the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences, shared his personal journey during the special session “From a Skilled Commander to a Strategic Leader.” He reflected on his transformation from a surgeon striving for technical perfection in the operating room to a discipline leader committed to cultivating teams and advancing the field as a whole.
AOT 2026 | Professor Matthias Stelljes: Therapeutic Pathways and Key Decision-Making Considerations in Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

AOT 2026 | Professor Matthias Stelljes: Therapeutic Pathways and Key Decision-Making Considerations in Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

To comprehensively improve public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become key drivers of clinical progress. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Conference (AOT) was successfully held in Beijing from April 24 to 25, 2026. Organized by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care and hosted by the National Clinical Research Center for Hematologic Diseases and the Peking University Institute of Hematology, this year’s conference centered on the theme “The Art of Transplantation.” The meeting brought together leading hematology experts from around the world to discuss cutting-edge innovations and future directions in hematopoietic stem cell transplantation.
AOT 2026 | Professor Donal P. McLornan: Challenges, Strategies, and Future Directions for Hematopoietic Stem Cell Transplantation in MDS/MPN

AOT 2026 | Professor Donal P. McLornan: Challenges, Strategies, and Future Directions for Hematopoietic Stem Cell Transplantation in MDS/MPN

To comprehensively improve public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become key drivers of clinical progress. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Conference (AOT) was successfully held in Beijing from April 24 to 25, 2026. Organized by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care and hosted by the National Clinical Research Center for Hematologic Diseases and the Peking University Institute of Hematology, this year’s conference centered on the theme “The Art of Transplantation.” The meeting brought together leading hematology experts from around the world to discuss cutting-edge innovations and emerging trends in hematopoietic stem cell transplantation.
Chronicles of Genitourinary Oncology · 2026 | Led by Professor Jun Guo, Experts Highlight the Year’s Landmark Breakthroughs in Genitourinary Cancer Care (Part II)

Chronicles of Genitourinary Oncology · 2026 | Led by Professor Jun Guo, Experts Highlight the Year’s Landmark Breakthroughs in Genitourinary Cancer Care (Part II)

From the first glimmer of insight in 1941, when Professor Charles Huggins discovered the hormone dependence of prostate cancer, to today’s flourishing era of precision oncology, the field of genitourinary cancers has traveled an extraordinary path—from silence and therapeutic limitation to an age of precision-driven breakthroughs. As both a participant in and witness to this journey, I feel deeply honored and profoundly inspired.
The 4th Urologic Oncology Clinical Research Conference | Professor Jun Guo on the Innovation Momentum and Future Direction of Chinese Genitourinary Oncology Research

The 4th Urologic Oncology Clinical Research Conference | Professor Jun Guo on the Innovation Momentum and Future Direction of Chinese Genitourinary Oncology Research

The 4th Urologic Oncology Clinical Research Conference brought together leading experts, investigators, and innovators to review the latest progress in genitourinary oncology research in China. Alongside academic forums and international expert discussions, the meeting also released the 2025 Annual Report on Chinese Genitourinary Oncology Clinical Research, offering a comprehensive overview of the field’s recent development.